egb761, a ginkgo biloba extract, is effective against atherosclerosis in vitro, and in a rat model of type 2 diabetesegb761、银杏叶提取物对动脉粥样硬化在体外有效,在2型糖尿病大鼠模型.pdfVIP

EGb761, a Ginkgo Biloba Extract, Is Effective Against Atherosclerosis In Vitro, and in a Rat Model of Type 2 Diabetes 1,2. 1,2. 1,2 1,2 1 2 Soo Lim , Ji Won Yoon , Seon Mee Kang , Sung Hee Choi , Bong Jun Cho , Min Kim , Ho Seon 2 2 3 4 2 1,2 2 Park , Hyun Ju Cho , Hayley Shin , Young-Bum Kim , Hyo Soo Kim , Hak Chul Jang , Kyong Soo Park * 1 Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, 2 Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea, 3 Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America, 4 Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts, United States of America Abstract Background: EGb761, a standardized Ginkgo biloba extract, has antioxidant and antiplatelet aggregation and thus might protect against atherosclerosis. However, molecular and functional properties of EGb761 and its major subcomponents have not been well characterized. We investigated the effect of EGb761 and its major subcomponents (bilobalide, kaemferol, and quercetin) on preventing atherosclerosis in vitro, and in a rat model of type 2 diabetes. Methods and Results: EGb761 (100 and 200 mg/kg) or normal saline (control) were administered to Otsuka Long-Evans Tokushima Fatty rats, an obese insulin-resist